Results 111 to 120 of about 1,518 (207)

Itch-free state in patients with atopic dermatitis treated with ruxolitinib cream: A pooled analysis from two randomized phase 3 studies

, 2022
Andrew Blauvelt, Jacek C. Szepietowski, Kim Papp, Eric L. Simpson, Jonathan I. Silverberg, Brian Kim, Shawn G. Kwatra, Michael E. Kuligowski, May E. Venturanza, Shaoceng Wei, Leon Kircik   +10 more
openalex   +1 more source

325 Ruxolitinib cream rapidly decreases skin pain in atopic dermatitis [PDF]

Journal of Investigative Dermatology, 2021
A. Blauvelt, J.C. Szepietowski, K. Papp, E. Simpson, J.I. Silverberg, B.S. Kim, S.G. Kwatra, M.E. Kuligowski, M.E. Venturanza, K. Sun, L. Kircik   +10 more
openaire   +1 more source

Efficacy, safety, and treatment patterns of ruxolitinib 1.5% cream in adult atopic dermatitis: A single center retrospective study [PDF]

, 2023
Nicole S. Stefanko, Victor L. Quan, Raj Chovatiya   +2 more
openalex   +1 more source

303 Maintenance of Repigmentation After Discontinuation of Ruxolitinib Cream in Patients With Vitiligo [PDF]

, 2021
David Rosmarin, Amit G. Pandya, Pearl Grimes, Mark Lebwohl, A.B. Gottlieb, Iltefat Hamzavi, Kathleen Butler, Shaoceng Wei, Beth Rumberger, John E. Harris   +9 more
openalex   +1 more source

Topical Tofacitinib for Atopic Dermatitis – Outcomes from Randomized Phase 3 Clinical Trial: First Approval

Indian Journal of Dermatology
Background: The Janus kinase (JAK) enzyme plays a crucial role in the pathophysiology of atopic dermatitis (AD). The United States Food and Drug Administration (USFDA) has recently granted approval for three JAK inhibitors intended for AD treatment ...
Alok R. Chaturvedi, Hemant G. Zaveri, Dhaval V. Patel, Tof-O in AD Trial Investigators   +3 more
doaj   +1 more source

Efficacy and Safety of JAK Inhibitors in the Management of Vitiligo: A Systematic Review and Meta-analysis

Dermatology and Therapy
Introduction Vitiligo, a chronic skin disease affecting 1–2% of the global population, is associated with significant impairment in quality of life. Current pharmacological treatment options have limited efficacy and considerable side effects.
Alzahra A. Mohammed, Anna S. Lengyel, Fanni A. Meznerics, István Szondy, Anna Walter, Bence Szabó, Dorottya Pál, Adrienn Bojtor, András Bánvölgyi, Norbert Kiss, Péter Hegyi, Lajos V. Kemény, Zsuzsanna Kurgyis   +12 more
doaj   +1 more source

Assessing Participants’ Experiences with Vitiligo from Patient Interviews

Dermatology and Therapy
Introduction Vitiligo is an autoimmune disease, causing skin depigmentation. Individuals with vitiligo incur substantial psychosocial burden and have expressed frustration with their treatments.
Amit G. Pandya, Theresa Amoloja, Kristen Bibeau, Dana DiBenedetti, Katherine Kosa, Kathleen Butler, Deanna Kornacki, Khaled Ezzedine   +7 more
doaj   +1 more source

Canadian Consensus Guidelines for the Management of Vitiligo

Dermatology and Therapy
Introduction Vitiligo remains a highly burdensome disease associated with significant autoimmune and psychosocial comorbidities. Although the therapeutic landscape has long been dominated by off-label therapy, new treatments are emerging.
Vimal H. Prajapati, Harvey Lui, Yvette Miller-Monthrope, Julien Ringuet, Irina Turchin, H. Chih-ho Hong, Charles Lynde, Kim A. Papp, Jensen Yeung, Melinda J. Gooderham   +9 more
doaj   +1 more source

Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Results From Two Phase 3, Randomized, Double-Blind Studies [PDF]

, 2020
Kim Papp, Jacek C. Szepietowski, Leon Kircik, Darryl Toth, Michael E. Kuligowski, May E. Venturanza, Kang Sun, Eric L. Simpson   +7 more
openalex   +1 more source

CO96 Subgroup Analysis of Quality of Life and Treatment Satisfaction By Baseline Patient Characteristics: Pooled Results from Two Randomized Phase 3 Studies of Ruxolitinib Cream for the Treatment of Vitiligo [PDF]

, 2022
AG Pandya, Nanja van Geel, Kathleen Butler, Kristen Bibeau, Jessy Gao, Khaled Ezzedine   +5 more
openalex   +1 more source